gaboxadol has been researched along with Parkinson Disease, Secondary in 1 studies
gaboxadol: GABA agonist; inhibitor of GABA uptake systems; structure
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Side effects included sedation, confusion, dizziness, vomiting, and myoclonic jerks." | 2.65 | The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist. ( Casey, DE; Gerlach, J; Hetmar, O; Kaldan, B; Korsgaard, S; Mikkelsen, LB, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Korsgaard, S | 1 |
| Casey, DE | 1 |
| Gerlach, J | 1 |
| Hetmar, O | 1 |
| Kaldan, B | 1 |
| Mikkelsen, LB | 1 |
1 trial available for gaboxadol and Parkinson Disease, Secondary
| Article | Year |
|---|---|
The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist.
Topics: Adult; Aged; Analgesics; Antipsychotic Agents; Blinking; Clinical Trials as Topic; Confusion; Dizzin | 1982 |